Jurgen Moll,
Riccardo Colombo
Humana Press
e druk, 2016
9781493962785
Target Identification and Validation in Drug Discovery
Methods and Protocols
Specificaties
Paperback, blz.
|
Engels
Humana Press |
e druk, 2016
ISBN13: 9781493962785
Rubricering
Onderdeel van serie
Methods in Molecular Biology
Verwachte levertijd ongeveer 9 werkdagen
Samenvatting
The major reason for the elevated costs of drug development in the pharmaceutical industry is the high attrition rate. In Target Identification and Validation in Drug Discovery: Methods and Protocols, expert researchers in the field detail many of the methods which are now commonly used to identify and validate new target. These include methods and approaches covering biochemical, cell based, in vivo models and translational methods. Chapters also include selected case reports that demonstrate the integration of these technologies to real life experiences and to demonstrate the multiple use of more than one technology to increase knowledge on a specific target. These Written in the highly successful Methods in Molecular Biology™ series format, the chapters include the kind of detailed description and implementation advice that is crucial for getting optimal results in the laboratory.
Thorough and intuitive, Target Identification and Validation in Drug Discovery: Methods and Protocols contains a comprehensive list of essential methods and clear protocols to follow.
Specificaties
Inhoudsopgave
<p>Part I- Background</p><p> </p><p>1. The Path to Oncology Drug Target Validation – an Industry Perspective</p><p> </p><p>Marta Cortés-Cros, Tobias Schmelzle, Volker M. Stucke and Francesco Hofmann</p><p> </p><p> </p><p> </p><p>Part II- DNA as a tool to Modulate Drug Targets</p><p> </p><p>2. Identification of Aptamers as Specific Binders and Modulators of Cell-Surface Receptor Activity</p><p> </p><p>Henning Ulrich and Carsten Wrenger</p><p> </p><p> </p><p> </p><p>3. The Design and Structure-functional Properties of DNA-based Immunomodulatory Sequences</p><p> </p><p>Nikolai V. Kuznetsov</p><p> </p><p> </p><p> </p><p>Part III-RNA Interference : From Design to Data Analysis</p><p> </p><p>4. siRNA Design Principles and Off-target Effects</p><p> </p><p>Sebastian Petri and Gunter Meister</p><p> </p><p> </p><p> </p><p>5. Western Blot Evaluation of siRNA Delivery by pH Responsive Peptides</p><p> </p><p>Wanling Liang, A. James Mason and Jenny K.W. Lam</p><p> </p><p> </p><p> </p><p>6. High Throughput RNAi Screening for the Identification of Novel Targets</p><p> </p><p>Meredith C. Henderson and David O. Azorsa</p><p> </p><p> </p><p> </p><p>7. Integration of RNAi and Small Molecule Screens to Identify Targets for Drug Development</p><p> </p><p>Konstantinos Drosopoulos and Spiros Linardopoulos</p><p> </p><p> </p><p> </p><p>8. CellProfiler and KNIME: Open Source Tools for High Content Screening</p><p> </p><p>Martin Stöter, Antje Niederlein, Rico Barsacchi, Felix Meyenhofer, Holger Brandl and Marc Bickle</p><p> </p><p> </p><p> </p><p>9. PARP Inhibition as a Prototype for Synthetic Lethal Screens</p><p> </p><p>Xuesong Liu</p><p> </p><p> </p><p> </p><p>Part IV-Protein Focused Technologies</p><p> </p><p>10. Structure-Based Target Druggability Assessment</p><p> </p><p>Jean-Yves Trosset and Nicolas Vodovar</p><p> </p><p> </p><p> </p><p>11. Validating Pharmacological Disruption of Protein-protein Interactions by Acceptor Photobleaching FRET Imaging</p><p> </p><p>Janos Roszik, Gábor Tóth, János Szöllősi and György Vereb</p><p> </p><p> </p><p> </p><p>12. Systematic Analysis of Complex Signal Transduction Pathways using Protein Fragment Complementation Assays</p><p> </p><p>Thomas I. Koblizek, Ann Siehoff and Anthony Pitt</p><p> </p><p> </p><p> </p><p>13. Reverse-Phase Protein Microarrays and Their Utility in Drug Development</p><p> </p><p>Maria Isabella Sereni , Mariaelena Pierobon,Roberto Angioli Emanuel F. Petricoin III, and Mitchell J. Frederick</p><p> </p><p> </p><p> </p><p>Part V. Innovative Cell Culture Techniques to Mimic Tissue Microenvironments</p><p> </p><p>14. A Cell Culture System that Mimics Chronic Lymphocytic Leukemia Cells Microenvironment for Drug Screening and Characterization </p><p> </p><p>Alessandro Natoni</p><p> </p><p> </p><p> </p><p>15. 2-Dimensional vs. 3-Dimensional in vitro Tumor Migration and Invasion Assays</p><p> </p><p>Miriam Zimmermann, Carol Box and Suzanne A. Eccles</p><p> </p><p> </p><p> </p><p>16. Tumor Spheroid-based Migration Assays for Evaluation of Therapeutic Agents</p><p> </p><p>Maria Vinci, Carol Box, Miriam Zimmermann and Suzanne A. Eccles </p><p> </p><p> </p><p> </p><p>17. The NeuroSphere Assay (NSA) Applied to Neural Stem Cells (NSCs) and Cancer Stem Cells (CSCs)</p><p> </p><p>Rossella Galli</p><p> </p><p> </p><p>Part VI- Genetically Engineered Animal Models to study Gene Functions</p><p> </p><p>18. Genetically Engineered Animal Models for in vivo Target Identification and Validation in Oncology</p><p>Gemma Texidó</p><p> </p><p> </p><p> </p><p>19. Target Validation in Mice by Constitutive and Conditional RNAi</p><p> </p><p>Aljoscha Kleinhammer, Wolfgang Wurst, Ralf Kühn </p><p> </p><p> </p><p> </p><p>20. In vivo Target Validation by Inducible RNAi in Human Xenograft Mouse Models</p><p> </p><p>Marco Mazzoletti and Gemma Texido</p><p> </p><p> </p><p> </p><p>Part VII- Translational Methods to validate Biomarkers</p><p> </p><p>21. Brightfield In Situ Hybridization Methods to Discover Gene Amplifications and Rearrangements in Clinical Samples</p><p> </p><p>Hiroaki Nitta and Thomas M. Grogan</p><p> </p><p> </p><p> </p><p>22. Combined microRNA In Situ Hybridization and Immunohistochemical Detection of Protein Markers</p><p> </p><p>Boye Schnack Nielsen and Kim Holmstrøm</p><p> </p><p> </p><p> </p><p>Thomas I. Koblizek, Ann Siehoff and Anthony Pitt</p><p> </p><p> </p>
